Get detailed insights into the current valuation of Cancer Microbiome market size, including growth analysis, current market status and future market projections.

This statistic shows the global cancer microbiome sequencing market share in 2020 and 2031, by application area. It was estimated that the translational research segment held almost 77 percent of the total global market in 2020. It was forecast that by 2031 this share will decrease to around 74 percent.

This statistic shows the global cancer microbiome sequencing market in 2020 and a forecast for 2031. It was estimated that the total global market in 2020 was worth around 156 million U.S. dollars. It was forecast that the market will increase to some 1.22 billion dollars by 2031.

The Human Microbiome Market is segmented by Application (Therapeutics and Diagnostics), Disease (Obesity, Diabetes, Autoimmune Disorder, Cancer, Gastrointestinal Disorders, Central Nervous System Disorders, and Other Diseases), Product (Probiotics, Prebiotics, Symbiotic, and Other Products), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The Market Size and Forecasts are Provided in Terms of Value (USD Billion) for all the Above Segments in this Industry Report.

United States human microbiome market size reached US$ 308 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 1,377 Million by 2032, exhibiting a growth rate (CAGR) of 18.1% during 2024-2032. The increasing advances in sequencing technologies and bioinformatics tools, which have made it easier to characterize and understand the complex microbial communities within the human body, are driving the market.

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country level for 2024-2032. Our report has categorized the market based on product, application, and disease type.

Global Human Microbiome Market market size valued at US$ 743.1 Million in 2023, reach US$ 8300.65 Million by 2032 at a CAGR of 27.3% from 2024 to 2032.

Microbiome Sequencing Services Market size was valued at USD 1.26 billion in 2021 and is poised to grow from USD 1.39 billion in 2022 to USD 3.13 billion by 2030, growing at a CAGR of 10.7% in the forecast period (2023-2030).

Global microbiome sequencing services market size was worth around USD 1,527 million in 2023 and is predicted to grow to around USD 3,843 million by 2032

The composition of the vaginal microbiome, including both the presence of pathogens involved in sexually transmitted infections (STI) as well as commensal microbiota, has been shown to have important associations for a woman’s reproductive and general health. Currently, healthcare providers cannot offer comprehensive vaginal microbiome screening, but are limited to the detection of individual pathogens, such as high-risk human papillomavirus (hrHPV), the predominant cause of cervical cancer. There is no single test on the market that combines HPV, STI, and microbiome screening. Here, we describe a novel inclusive vaginal health assay that combines self-sampling with sequencing-based HPV detection and genotyping, vaginal microbiome analysis, and STI-associated pathogen detection. The assay includes genotyping and detection of 14 hrHPV types, 5 low-risk HPV types (lrHPV), as well as the relative abundance of 31 bacterial taxa of clinical importance, including Lactobacillus, Sneathia, Gardnerella, and 3 pathogens involved in STI, with high sensitivity, specificity, and reproducibility. For each of these taxa, reference ranges were determined in a group of 50 self-reported healthy women. The HPV sequencing portion of the test was evaluated against the digene High-Risk HPV HC2 DNA test. For hrHPV genotyping, agreement was 95.3% with a kappa of 0.804 (601 samples); after removal of samples in which the digene hrHPV probe showed cross-reactivity with lrHPV types, the sensitivity and specificity of the hrHPV genotyping assay were 94.5% and 96.6%, respectively, with a kappa of 0.841. For lrHPV genotyping, agreement was 93.9% with a kappa of 0.788 (148 samples), while sensitivity and specificity were 100% and 92.9%, respectively. This novel assay could be used to complement conventional cervical cancer screening, because its self-sampling format can expand access among women who would otherwise not participate, and because of its additional information about the composition of the vaginal microbiome and the presence of pathogens.

The Laboratory Automation Systems Market Analysis is Segmented by Type of Equipment (Automated Liquid Handlers, Automated Plate Handlers, Robotic Arms, Automated Storage and Retrieval Systems (ASRS), and Analyzers), by Software (Laboratory Information Management System (LIMS), Laboratory Information System (LIS), Chromatography Data System (CDS), Electronic Lab Notebook (ELN), and Scientific Data Management System (SDMS)), Application (Drug Discovery, Genomics, Proteomics, Clinical Diagnostics), and by Geography (North America, Europe, Asia Pacific, Rest of the World). The Report Offers Market Forecasts and Size in Value (USD) for all the Above Segments.